Stemline wraps positive pivotal trial for its controversial lead cancer drug, clearing a path to the FDA
Back in February, Stemline Therapeutics $STML managed to put itself in the middle of a controversy when it rolled out a $45 million offering …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
